Koers MannKind Corporation Nasdaq
Aandelen
US56400P2011
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | 260 mln. 244 mln. | Omzet 2025 * | 313 mln. 294 mln. | Marktkapitalisatie | 1,11 mld. 1,04 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 38 mln. 35,66 mln. | Nettowinst (verlies) 2025 * | 73 mln. 68,51 mln. | EV/omzet 2024 * | 3,33 x |
Nettoliquiditeiten 2024 * | 248 mln. 233 mln. | Nettoliquiditeiten 2025 * | 273 mln. 256 mln. | EV/omzet 2025 * | 2,69 x |
K/w-verhouding 2024 * |
31,1
x | K/w-verhouding 2025 * |
18
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,47% |
Recentste transcriptie over MannKind Corporation
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 47 | 14-03-16 |
Sanjay Singh
CTO | Chief Tech/Sci/R&D Officer | 57 | 01-10-22 |
Kevin Kaiserman
CTO | Chief Tech/Sci/R&D Officer | - | 31-08-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 55 | 27-11-18 | |
Anthony Hooper
BRD | Director/Board Member | 69 | 01-01-20 |
Ronald Consiglio
BRD | Director/Board Member | 80 | 01-10-03 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,46% | 102 mld. | |
+1,41% | 96,09 mld. | |
+2,13% | 22,28 mld. | |
-15,84% | 21,4 mld. | |
-9,21% | 18,14 mld. | |
-39,98% | 17,02 mld. | |
-14,65% | 16,09 mld. | |
+4,39% | 13,83 mld. | |
+31,35% | 11,97 mld. |
- Beurs
- Aandelen
- Koers MNKD
- Koers